

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boill Healthcare Holdings Limited

保集健康控股有限公司

(formerly known as “Ngai Shun Holdings Limited 毅信控股有限公司”)

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 01246)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE OF COMPOSITION OF BOARD COMMITTEES

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that with effect from 15 November 2017, Mr. Chan Chi Keung, Billy has been appointed as an independent non-executive Director.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

Following the appointment of the independent non-executive Director and with effect from 15 November 2017, Mr. Chan has been appointed as a member of each of the audit committee, the nomination committee and the remuneration committee.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of Boill Healthcare Holdings Limited (the “**Company**”) is pleased to announce that Mr. Chan Chi Keung, Billy (“**Mr. Chan**”) has been appointed as an independent non-executive Director with effect from 15 November 2017. The biographical details of Mr. Chan are set out as follows:

Mr. Chan, aged 44, graduated from Hong Kong Baptist University with an Honours Degree with major in Accounting. He is a fellow member of the Association of Chartered Certified Accountants. Mr. Chan has over 20 years’ experience in auditing, accounting and financial management. He is the financial controller, company secretary, and one of the authorised representatives of Fortunet e-Commerce Group Limited (stock code 1039). He had worked in South China Media Group for 15 years from December 1999 to May 2015 and his latest position was the deputy financial controller. He had worked in South China Land Limited (formerly named as Capital Publications Limited, stock code 8155) from January 2004 to June 2008 as the qualified accountant and company secretary.

On 15 November 2017, Mr. Chan entered into an appointment letter (the “**Appointment Letter**”) with the Company, pursuant to which he is appointed for an initial term of one year commencing from 15 November 2017 unless terminated by either party to the Appointment Letter, which requires not less than three months’ prior notice for termination thereof. He will hold office until the forthcoming general meeting of the Company and will retire at that general meeting but will be eligible for re-election pursuant to the memorandum and articles of association of the Company. Pursuant to the Appointment Letter, Mr. Chan is entitled to a director’s fee of HK\$120,000 per annum, which has been approved by the remuneration committee of the Company with reference to, among others, his qualification, experience, duties, potential contributions to the Company and the prevailing market conditions.

Save as disclosed above, Mr. Chan does not hold any position in the Company or any of its subsidiaries, or have any other major appointments and professional qualifications. He does not have any relationship with any Directors, senior management or substantial or controlling Shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) of the Company.

Moreover, as at the date of this announcement, Mr. Chan does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (as defined under Part XV of the SFO) of the Company.

Save as disclosed above, Mr. Chan did not hold any other directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the three years prior to the date of this announcement.

Save as disclosed above, there are no other matters concerning Mr. Chan that need to be brought to the attention of the Shareholders nor is there any information relating to Mr. Chan that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

The Board announces that, following the appointment of the independent non-executive Director and with effect from 15 November 2017, Mr. Chan has been appointed as a member of each of the audit committee, the nomination committee and of the remuneration committee the Company.

The Board would like to take this opportunity to extend its warmest welcome to Mr. Chan for joining the Board.

By order of the Board of
Boill Healthcare Holdings Limited
Dai Dong Xing
Executive Director and Chairman

Hong Kong, 15 November 2017

As at the date of this announcement, the Company has (i) four executive Directors, namely Mr. Dai Dong Xing, Mr. Mock Wai Yin, Dr. Wong Yun Kuen, and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) four independent non-executive Directors, namely Mr. Xu Liang Wei, Mr. Wang Zhe, Mr. Hua Shan and Mr. Chan Chi Keung, Billy.

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.